For the Inventor, By the Inventor

Enter assignee name

Pittsburgh, PA, United States of America

Knopp Biosciences, LLC

Calculating rank

USPTO Granted Patents = 27

EPO Patents = 8

Trademarks = 2

Forward Citations = 114

Loading Chart...

Loading Chart...

33 inventors (with patents filed for the assignee):

Michael E Bozik (17 out of 26 patents)

Steven Dworetzky (11 out of 14 patents)

Thomas Petzinger, Jr (10 out of 17 patents)

4. Lynn Resnick (9 out of 14 patents)

5. George T Topalov (9 out of 31 patents)

6. Charles A Flentge (9 out of 14 patents)

7. David A Mareska (9 out of 25 patents)

8. James S Hale (9 out of 14 patents)

9. Justin K Belardi (8 out of 12 patents)

10. Scott S Harried (8 out of 30 patents)

11. Gregory Hebrank (6 out of 9 patents)

12. Wildon Farwell (6 out of 8 patents)

13. Kai Zhang (4 out of 4 patents)

14. Donald Archibald (3 out of 3 patents)

15. James L Mather (3 out of 3 patents)

Core Competencies:

Kv7 Channel Activators

Eosinophils

Chronic Urticaria

Amyotrophic Lateral Sclerosis

Plasma Cell Disorders

B-Cell Prolymphocytic Disorders

Benzoimidazol Amides

Tetrahydrobenzothiazole Compounds

27 patents: Sort by Forward Citations

1. 11261162 - KV7 channel activators compositions and methods of use (2022-03-01),

2. 11026928 - Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils (2021-06-08),

3. 10980783 - Compositions and methods for treating conditions related to increased eosinophils (2021-04-20),

4. 10906877 - Benzoimidazol-1,2-yl amides as Kv7 channel activators (2021-02-02),

5. 10851067 - Kv7 channel activators compositions and methods of use (2020-12-01),

6. 10828284 - Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils (2020-11-10),

7. 10526328 - Imidazo[4,5-b]pyridin-2-yl amides as Kv7 channel activators (2020-01-07),

8. 10456381 - Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders (2019-10-29),

9. 10385025 - Benzoimidazol-1,2-yl amides as Kv7 channel activators (2019-08-20),

10. 10383857 - Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils (2019-08-20),

11. 10383856 - Compositions and methods for treating conditions related to increased eosinophils (2019-08-20),

12. 10285981 - Compositions and methods for treating amyotrophic lateral sclerosis in responders (2019-05-14),

13. 10208003 - Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds (2019-02-19),

14. 10195183 - Compositions and methods for treating chronic urticaria (2019-02-05),

15. 10179774 - Synthesis of chirally purified substituted benzothiazole diamines (2019-01-15),

Company Overview

Knopp Biosciences, LLC is a biopharmaceutical company based in Pittsburgh, PA, focused on developing innovative therapies for neurological disorders and other serious medical conditions. The company specializes in the discovery and advancement of novel small molecule drugs, leveraging its expertise in pharmacology and drug development. Knopp's research emphasizes addressing unmet medical needs through targeted treatments, aiming to improve patient outcomes and enhance quality of life.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

27 Patents

#91 in Pittsburgh, PA

#454 in Pennsylvania

#12,436 in US

#24,055 in the World

Pittsburgh, PA, United States of America

Knopp Biosciences, LLC

Forward Citations = 114

33 inventors:

Michael E Bozik (17 out of 26 patents)

Steven Dworetzky (11 out of 14 patents)

Thomas Petzinger, Jr (10 out of 17 patents)

4. Lynn Resnick (9 out of 14 patents)

5. George T Topalov (9 out of 31 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Knopp Biosciences, LLC. Retrieved from https://idiyas.com/company/knopp-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…